Production (Stage)
ARYx Therapeutics, Inc.
ARYX
$0.00
$0.000.00%
OTC PK
| 09/30/2010 | 06/30/2010 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -38.45% | -10.05% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -31.73% | -31.98% | |||
| Operating Income | 31.73% | 31.98% | |||
| Income Before Tax | 30.86% | 43.10% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 30.86% | 43.10% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 30.86% | 43.10% | |||
| EBIT | 31.73% | 31.98% | |||
| EBITDA | 33.39% | 33.36% | |||
| EPS Basic | 30.91% | 50.07% | |||
| Normalized Basic EPS | 28.90% | 37.99% | |||
| EPS Diluted | 30.91% | 50.07% | |||
| Normalized Diluted EPS | 28.90% | 37.99% | |||
| Average Basic Shares Outstanding | 0.01% | 13.99% | |||
| Average Diluted Shares Outstanding | 0.01% | 13.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||